Close
Close

Catherine Cibulskis, MD - Cholestasis

Partner

Not provided

Rare Disease

Cholestasis

Sponsor

Catherine Cibulskis, MD

Access Program Information

This is a compassionate use protocol of an investigational new drug (IND). The overall purpose of the treatment is to offer alternative treatment to children who developed parenteral nutrition-associated liver disease (PNALD) and have not responded positively to currently available medical therapies. PNALD develops in newborns dependent on parenteral nutrition (PN) and are unable to tolerate adequate enteral feedings to support fluid and nutritional fluids; although PN is necessary and life sustaining, it can result in severe liver disease.

Contact

Contact: Catherine Cibulskis, MD (314-577-5642)

Locations
  • United States
  • Saint Louis, Missouri, United States

Free Newsletter